Details
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | 396 |
| Fachzeitschrift | NUTRIENTS |
| Jahrgang | 14 |
| Ausgabenummer | 2 |
| Publikationsstatus | Veröffentlicht - 17 Jan. 2022 |
Abstract
The intermediate state between normal glucose tolerance and overt type 2 diabetes mellitus is associated with micro-and macrovascular diseases, requiring safe and cost-effective treatment measures interventions. A novel source of LC n-3 FAs is Calanus finmarchicus Oil, which showed promising effects on glucose homeostasis in preclinical studies due to anti-obesity effects and/or anti-inflammatory properties. In total, 43 obese patients (BMI: 31.7 ± 5.2 kg/m2) were allocated in the following two groups: (1) Calanus oil group (2 g CO/day) and (2) placebo group (2 g paraffin oil/day). Markers of glucose metabolism, body composition and energy intake were measured at the beginning (t0), after 12 weeks (t12) and 16 weeks (t16). Overall, parameters reflecting abnormal glucose homeostasis and insulin resistance in the liver, including fasting insulin (−2.9 mU/L ± 4.10, p < 0.05), HOMA-IR (−0.9 ± 1.28, p < 0.05) and hepatic insulin resistance index (−1.06 ± 1.72 × 106, p < 0.05) significantly enhanced after a 12-week CO-intervention, while no differences were observed in HbA1c, AUC0–2h Glucose, AUC0–2h Insulin, 2 h plasma glucose and muscle insulin sensitivity in-dex. Our results indicate that Calanus oil causes beneficial effects on glucose metabolism and insulin resistance in obese patients, with clinical relevance to be verified in further studies. In addition, the possible active compounds and their mechanisms of action should be elucidated.
ASJC Scopus Sachgebiete
- Agrar- und Biowissenschaften (insg.)
- Lebensmittelwissenschaften
- Pflege (insg.)
- Ernährung und Diätetik
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: NUTRIENTS, Jahrgang 14, Nr. 2, 396, 17.01.2022.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Marine Oil from C. finmarchicus Enhances Glucose Homeostasis and Liver Insulin Resistance in Obese Prediabetic Individuals
AU - Burhop, Milena
AU - Schuchardt, Jan Philipp
AU - Nebl, Josefine
AU - Müller, Mattea
AU - Lichtinghagen, Ralf
AU - Hahn, Andreas
N1 - Funding Information: Funding: This research was partially funded by Calanus AS, grant number 60422304.
PY - 2022/1/17
Y1 - 2022/1/17
N2 - The intermediate state between normal glucose tolerance and overt type 2 diabetes mellitus is associated with micro-and macrovascular diseases, requiring safe and cost-effective treatment measures interventions. A novel source of LC n-3 FAs is Calanus finmarchicus Oil, which showed promising effects on glucose homeostasis in preclinical studies due to anti-obesity effects and/or anti-inflammatory properties. In total, 43 obese patients (BMI: 31.7 ± 5.2 kg/m2) were allocated in the following two groups: (1) Calanus oil group (2 g CO/day) and (2) placebo group (2 g paraffin oil/day). Markers of glucose metabolism, body composition and energy intake were measured at the beginning (t0), after 12 weeks (t12) and 16 weeks (t16). Overall, parameters reflecting abnormal glucose homeostasis and insulin resistance in the liver, including fasting insulin (−2.9 mU/L ± 4.10, p < 0.05), HOMA-IR (−0.9 ± 1.28, p < 0.05) and hepatic insulin resistance index (−1.06 ± 1.72 × 106, p < 0.05) significantly enhanced after a 12-week CO-intervention, while no differences were observed in HbA1c, AUC0–2h Glucose, AUC0–2h Insulin, 2 h plasma glucose and muscle insulin sensitivity in-dex. Our results indicate that Calanus oil causes beneficial effects on glucose metabolism and insulin resistance in obese patients, with clinical relevance to be verified in further studies. In addition, the possible active compounds and their mechanisms of action should be elucidated.
AB - The intermediate state between normal glucose tolerance and overt type 2 diabetes mellitus is associated with micro-and macrovascular diseases, requiring safe and cost-effective treatment measures interventions. A novel source of LC n-3 FAs is Calanus finmarchicus Oil, which showed promising effects on glucose homeostasis in preclinical studies due to anti-obesity effects and/or anti-inflammatory properties. In total, 43 obese patients (BMI: 31.7 ± 5.2 kg/m2) were allocated in the following two groups: (1) Calanus oil group (2 g CO/day) and (2) placebo group (2 g paraffin oil/day). Markers of glucose metabolism, body composition and energy intake were measured at the beginning (t0), after 12 weeks (t12) and 16 weeks (t16). Overall, parameters reflecting abnormal glucose homeostasis and insulin resistance in the liver, including fasting insulin (−2.9 mU/L ± 4.10, p < 0.05), HOMA-IR (−0.9 ± 1.28, p < 0.05) and hepatic insulin resistance index (−1.06 ± 1.72 × 106, p < 0.05) significantly enhanced after a 12-week CO-intervention, while no differences were observed in HbA1c, AUC0–2h Glucose, AUC0–2h Insulin, 2 h plasma glucose and muscle insulin sensitivity in-dex. Our results indicate that Calanus oil causes beneficial effects on glucose metabolism and insulin resistance in obese patients, with clinical relevance to be verified in further studies. In addition, the possible active compounds and their mechanisms of action should be elucidated.
KW - Glucose metabolism
KW - Inflammation
KW - Insulin resistance
KW - Intermediate hyperglycaemia
KW - Marine oil
KW - Prediabetes
UR - http://www.scopus.com/inward/record.url?scp=85122830875&partnerID=8YFLogxK
U2 - 10.3390/nu14020396
DO - 10.3390/nu14020396
M3 - Article
AN - SCOPUS:85122830875
VL - 14
JO - NUTRIENTS
JF - NUTRIENTS
SN - 2072-6643
IS - 2
M1 - 396
ER -